Science Pool

Mitobiogenesis (or mitochondrial biogenesis) is defined as the growth and division of pre-existing mitochondria. Drug-induced perturbations in this process can result in mitochondrial dysfunction or toxicity. 

In this presentation, we focus on:

• mechanisms involved in mitochondrial toxicity including drug-induced mitobiogenesis
• the development of a high throughput high content imaging assay for detecting drug-induced effects on mitobiogenesis
• validation of the assay using known drugs which inhibit mitochondrial DNA and protein synthesis (e.g., antibiotics, anti-viral and anticancer drugs) as well as some non-mitochondrial toxicants.

View the presentation to learn more!

LEARN MORE

The brain is a complex organ. Find out more about the use of in vitro 3D co-culture brain microtissues for predicting human CNS liability.

In this presentation, we focus on:

• a background to drug-induced brain neurotoxicity
• the importance of astrocytes and their function
• the use of brain 3D co-cultured microtissues
• neurotransmitter pathway development over time
• high content screening (HCS) of brain microtissues and validation data

View the presentation to learn more!

LEARN MORE

Cardiotoxicity is a key cause of late stage attrition in drug development. iPSC-derived cardiomyocytes remain viable for more than 2 weeks on MEA plates. As MEA measures electrical activity without addition of any reagents, the cells can be exposed and monitored over extended time periods.

In this presentation, we focus on:

• a background to MEA
• design of the assay for detecting cardiotoxicity following chronic exposure to drugs
• case studies for cardiotoxic drugs with different mechanisms (hERG traffickers, multichannel blockers, specific ion channel effects)

View the presentation to learn more!

LEARN MORE